GLP-1 & Incretin Science

More Weight Lost, No More Pain Relieved

UKPWritten and published by UK Peptides3 min readUpdated 2 cited sources

The short answer

TRIUMPH-4's higher dose arm lost 2.3 percentage points more body weight than the lower one but reported marginally less pain relief and fewer complete resolutions. That dissociation has several possible explanations, and the tempting one, a direct non-mechanical effect, is the weakest supported.

Key facts

Trial
TRIUMPH-4 (NCT05931367)
Weight, lower dose arm
-26.4% (efficacy estimand)
Weight, higher dose arm
-28.7% (efficacy estimand)
WOMAC pain, lower dose arm
-4.5 points (-75.8%)
WOMAC pain, higher dose arm
-4.4 points (-74.3%)
Complete resolution, lower dose
14.1%
Complete resolution, higher dose
12.0%
Discontinuation, lower vs higher
12.2% vs 18.2%

The observation

Two active arms, one escalated to a higher dose than the other. The higher arm lost more weight: -28.7% against -26.4% on the efficacy estimand. On the pain endpoints it did not do better. WOMAC pain fell 4.4 points on the higher arm against 4.5 on the lower, and complete resolution of index knee pain was reported in 12.0% against 14.1%. If pain relief in knee osteoarthritis were a simple function of load removed from the joint, the arm that removed more load should have relieved more pain. It did not.

Reading one: the endpoint saturated

Mean baseline WOMAC pain was 6.0 on a 0-20 scale, and both arms removed about three-quarters of it. There is not much room left. An endpoint approaching its floor cannot register additional benefit, and the arm with more weight loss had nowhere to put it. This is the most parsimonious explanation and it is consistent with everything else in the trial, including the fact that both arms landed within 1.5 percentage points of each other in relative terms.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

Reading two: it is noise

TRIUMPH-4 randomised 445 people three ways, which puts roughly 148 in each arm. The trial was designed to compare each active arm against placebo, not the two active arms against each other, and no such comparison would be adequately powered. A 0.1-point difference on a 20-point scale and a two-percentage-point difference in a binary responder rate are the size of difference that appears and disappears between replicate trials. Treating them as findings is over-reading.

Reading three: the weight-pain relationship is non-linear

Joint loading falls with body mass, but the relationship between loading and pain need not be proportional across the whole range. If most of the symptomatic benefit accrues in the first fraction of weight lost, because that is what moves the joint out of the range where mechanical stress provokes symptoms, then additional weight loss beyond that point buys progressively less. On this reading the dissociation is real and mechanical, not evidence against a mechanical mechanism.

Reading four, and why it is the weakest

The tempting interpretation is that a component of the pain benefit is not mechanical at all (a direct effect on inflammation or nociception) and that this component plateaus while the weight effect does not. It is a coherent hypothesis and there is a plausible biological substrate for it. But it is not what this result shows. Absence of dose-tracking is a weak signal in both directions: it is equally consistent with saturation, with noise, and with non-linearity, all of which require no new mechanism. Inferring a direct effect from a null difference between two active arms is the kind of inference this class of data cannot support.

What the comparison does settle

One thing, clearly. The higher dose bought 2.3 percentage points more weight loss and six percentage points more discontinuation for adverse events (18.2% against 12.2%) while measuring no better on either pain endpoint. In a trial whose co-primary endpoints are weight and pain, that is a straightforward argument about dose selection, and it is the kind of trade-off that decides which dose a sponsor takes forward. It is also invisible to anyone who reads only the largest number in the release.

Frequently asked questions

Does this mean the higher dose is worse?

It means the higher dose was not better on the pain endpoints in this trial and was less well tolerated. Whether it is worse overall depends on which outcome is being optimised, in which population, and over what horizon. This trial was not designed to answer those questions.

Could the two arms have differed at baseline?

In a randomised trial of this size, small chance imbalances are expected and are one of the reasons unpowered between-arm comparisons are unreliable. The published topline does not provide arm-level baseline pain, so the possibility cannot be excluded from the available sources.

How would you actually test for a direct effect on pain?

By dissociating weight change from drug exposure: for example, comparing groups matched on weight loss achieved by different means, or looking at whether pain improves before meaningful weight is lost. Trials of that design are harder to run and rarer, which is why the question stays open.

Is this specific to retatrutide?

No. The same logic applies to any intervention where a downstream outcome might be mediated by an intermediate one. The general principle, that a null difference between two active arms is weak evidence for any mechanism, is not about this compound at all.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.